ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
8.75
+0.03 (0.34%)
At close: Jun 26, 2026, 4:00 PM EDT
8.73
-0.02 (-0.23%)
After-hours: Jun 26, 2026, 7:59 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 22.25, with a low estimate of 18 and a high estimate of 30. The average target predicts an increase of 154.29% from the current stock price of 8.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $18 | Buy | Maintains | $18 | +105.71% | Jun 15, 2026 |
| Raymond James | Raymond James | Buy Initiates $21 | Buy | Initiates | $21 | +140.00% | Jun 10, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $24 → $20 | Buy | Maintains | $24 → $20 | +128.57% | May 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades $30 | Hold | Downgrades | $30 | +242.86% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
534.90M
from 510.17M
Increased by 4.85%
Revenue Next Year
701.11M
from 534.90M
Increased by 31.07%
EPS This Year
0.81
from 0.66
Increased by 23.85%
EPS Next Year
1.00
from 0.81
Increased by 22.64%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 540.1M | 837.5M | |
| Avg | 534.9M | 701.1M | |
| Low | 529.9M | 599.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.9% | 56.6% | |
| Avg | 4.8% | 31.1% | |
| Low | 3.9% | 12.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.83 | 1.10 | |
| Avg | 0.81 | 1.00 | |
| Low | 0.78 | 0.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 26.4% | 35.2% | |
| Avg | 23.9% | 22.6% | |
| Low | 18.8% | 0.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.